Iron oxide nanoparticles are of particular interest for drug delivery applications, since they can be targeted to a specific location using a magnetic field. We are interested in delivering drugs to atherosclerotic plaques via these nanoparticles. However, prior to using nanoparticles in vivo, they must be shown as relatively non-toxic to cells. We and others have shown that bare iron oxide nanoparticles are readily taken up by cells, where they catalyze production of highly toxic reactive oxygen species . This oxidative stress disrupts the cell cytoskeleton, alters cell mechanics, and may change other critical cell functions. Iron oxide nanoparticles for in vivo biomedical applications are often coated with a polysaccharide (eg. dextran) or a polymer (eg. polyethylene glycol, PEG). Both the size and the surface coating of the nanoparticle play an important role in cell toxicity.
- Bioengineering Division
Iron Oxide Nanoparticles Are Less Toxic to Endothelial Cells When Coated With Dextran and Polyethylene Glycol
Yu, M, Muzykantov, V, & Clyne, AM. "Iron Oxide Nanoparticles Are Less Toxic to Endothelial Cells When Coated With Dextran and Polyethylene Glycol." Proceedings of the ASME 2011 Summer Bioengineering Conference. ASME 2011 Summer Bioengineering Conference, Parts A and B. Farmington, Pennsylvania, USA. June 22–25, 2011. pp. 1255-1256. ASME. https://doi.org/10.1115/SBC2011-53702
Download citation file: